Core Viewpoint - The company announced the cancellation of unvested restricted stock from its 2021, 2022, and 2023 A-share incentive plans due to the departure of certain incentive recipients and unmet performance targets [1][2]. Summary by Sections 1. Cancellation of Restricted Stocks - The company decided to cancel a total of 634,880 shares from the 2021, 2022, and 2023 A-share incentive plans due to the following reasons: - 42,189 shares from the 2021 plan due to one recipient's departure [2] - 44,104 shares from the 2022 plan due to ten recipients' departures [2] - 634,880 shares from the 2023 plan, which includes: - 179,553 shares due to ten recipients' departures - 455,327 shares due to unmet performance targets for the second vesting period [2][4] 2. Impact on the Company - The cancellation of these restricted stocks is not expected to have a material impact on the company's financial condition or operational results [2] - The stability of the core team is also not anticipated to be affected, and the incentive plans will continue to be implemented as planned [2] 3. Supervisory Board Opinion - The supervisory board reviewed the situation and agreed with the cancellation based on the reasons provided, confirming that the actions comply with relevant laws and regulations [3][4] 4. Legal Opinion - A legal opinion confirmed that the necessary authorizations and approvals for the cancellation have been obtained, and the actions are in accordance with applicable laws and the incentive plans [4]

Core Viewpoint - Kanglong Chemical reported a mixed performance in its semi-annual earnings, with revenue growth but a significant decline in net profit and earnings per share [2] Financial Performance - The company achieved approximately 6.441 billion yuan in revenue for the first half of 2025, representing a year-on-year increase of 14.93% [2] - The net profit attributable to shareholders was around 701 million yuan, showing a year-on-year decrease of 37% [2] - Basic earnings per share were 0.3984 yuan, down 36.58% compared to the previous year [2]

Group 1 - The core viewpoint of the article highlights that 康龙化成's stock price increased by 0.40% to 30.01 yuan as of August 21, 2025, with a trading volume of 336,003 hands and a transaction amount of 1.009 billion yuan [1] - 康龙化成 operates in the medical services sector, providing drug research outsourcing services, including drug discovery and preclinical and clinical research services for global pharmaceutical companies [1] - The company reported a revenue of 6.441 billion yuan for the first half of 2025, representing a year-on-year growth of 14.93%, while the net profit attributable to shareholders decreased by 37% to 701 million yuan, primarily due to significant investment gains from the disposal of PROTEOLOGIX, INC. in the previous year [1] Group 2 - On August 21, 2025, the net outflow of main funds was 75.8173 million yuan, with a cumulative net outflow of 302.7646 million yuan over the past five days [1]

Core Insights - The company reported a revenue of 6.441 billion yuan for the first half of 2025, representing a year-on-year increase of 14.93% [1] - The net profit attributable to shareholders decreased by 37.00% to 701 million yuan, while the net profit excluding non-recurring gains and losses increased by 36.66% to 637 million yuan [1] - Basic earnings per share were reported at 0.3984 yuan [1] Revenue Breakdown - Laboratory services generated a revenue of 3.892 billion yuan, up 15.46% year-on-year; in Q2 2025, revenue was 2.035 billion yuan, reflecting a quarter-on-quarter increase of 9.59% [2] - The gross margin for laboratory services was 45.20%, an increase of 0.74 percentage points compared to the same period last year [2] - New orders for laboratory services increased by over 10% year-on-year during the reporting period [2] CMC Services Performance - CMC (small molecule CDMO) services achieved a revenue of 1.39 billion yuan, a year-on-year growth of 18.20%; in Q2 2025, revenue was 697 million yuan, with a quarter-on-quarter increase of 0.53% [2] - The gross margin for CMC services was 30.50%, up 2.20 percentage points from the previous year [2] - New orders for CMC services grew approximately 20% year-on-year, driven by recovering customer demand and ongoing product pipeline advancements [2]

康龙化成8月21日晚间披露半年报，公司上半年实现营业收入64.41亿元，同比增长14.93%；归属于上市 公司股东的净利润7.01亿元，同比下降37%；基本每股收益0.3984元。 ...

Group 1 - The company reported a revenue of 6.441 billion yuan for the first half of 2025, representing a year-on-year growth of 14.93% [1] - The net profit attributable to shareholders of the listed company was 701 million yuan, showing a year-on-year decline of 37% [1] - The company announced plans not to distribute cash dividends, issue bonus shares, or increase share capital from reserves [1]

证券代码：300759 证券简称：康龙化成 公告编号：2025-043 康龙化成（北京）新药技术股份有限公司 关于追加投资境外参股公司暨关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、关联交易背景概述 2023 年 10 月 18 日，康龙化成（北京）新药技术股份有限公司（以下简称 "公司"）召开了第三届董事会第三次会议和第三届监事会第三次会议，分别审 议通过了《关于投资参股境外公司暨关联交易的议案》，同意公司以自有资金 1,050 万美元通过全资子公司 Pharmaron (Hong Kong) International Limited（以下 简称"康龙香港国际"）与合作方 CMS MEDICAL VENTURE PTE. LTD.（以下 简称"康哲药业"）、Rxilient Health Pte. Ltd.（以下简称"康联达"）、HEALTHY GOAL LIMITED（以下简称"君联基金"，君联基金和康龙香港国际、康哲药业、 康联达合称"全体投资人"）共同投资位于新加坡的 Rxilient Biohub Pte. Ltd.（现 更名 ...

| | | 占用方与上 | 上市公司核算 | 年期初 2025 | 2025 年半年度 2025 占用累计发生 | 年半年 | 年半年 2025 | 年半年 2025 | 占用形成 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | 市公司的关 | 的会计科目 | 占用资金余 | 度占用资金的 金额（不含利 | | 度偿还累计 | 度期末占用 | 原因 | 占用性质 | | | | 联关系 | | 额 | 利息（如有） | | 发生金额 | 资金余额 | | | | | | | | | 息） | | | | | | | 控股股东、实际控制人及 | | | | | | | | | | 非经营性占用 | | 其附属企业 | | | | | | | | | | 非经营性占用 | | 小计 | - | - | - | | | | | | | - | | 前控股股东、实际控制人 | | | | | | | | | | 非经营性占用 | | 及其附属企业 | | | | | | | | ...

人民财讯8月21日电，康龙化成（300759）8月21日晚间披露2025年半年度报告，上半年实现营业收入 64.41亿元，同比增长14.93%；归母净利润7.01亿元，同比下降37%；基本每股收益0.3984元。净利下滑 主要由于上年同期处置PROTEOLOGIX,INC.股权产生大额投资收益影响。 ...

证券代码：300759 证券简称：康龙化成 公告编号：2025-042 康龙化成（北京）新药技术股份有限公司 第三届监事会第十三次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 康龙化成（北京）新药技术股份有限公司（以下简称"公司"）第三届监事 会第十三次会议于 2025 年 8 月 21 日以通讯方式召开，本次会议通知于 2025 年 8 月 19 日以邮件形式向全体监事发出。会议应出席监事 3 名，实际出席监事 3 名。本次会议由监事会主席 Kexin Yang 博士主持，公司董事会秘书列席了本次 会议。本次会议的召集和召开符合《中华人民共和国公司法》等有关法律、行政 法规、部门规章、规范性文件和《康龙化成（北京）新药技术股份有限公司章程》 的规定。 二、监事会会议审议情况 与会监事审议并以记名投票方式通过了以下议案： （一）审议通过《关于 2025 年半年度报告全文、报告摘要及中期业绩公 告的议案》 监事会认为：公司编制的《2025 年半年度报告》《2025 年半年度报告摘要》 及《截至 2025 年 6 月 30 ...